SCHEMBL996402

SCHEMBL996402

COc1cc(O)c2c(=O)c3cc(O)ccc3oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 5/20 1.00
MAOA P21397 8/20 0.75
FASN P49327 1/20 0.71
MAPT P10636 3/20 0.67
KDM4E B2RXH2 2/20 0.67
LMNA P02545 2/20 0.67
ALDH1A1 P00352 1/20 0.67
HPGD P15428 1/20 0.67
ESR1 P03372 2/20 0.66
ESR2 Q92731 2/20 0.66
ACHE P22303 1/20 0.64
MAOB P27338 1/20 0.64
GAA P10253 1/20 0.59
SI P14410 1/20 0.59
MGAM2 Q2M2H8 1/20 0.59
IP6K2 Q9UHH9 2/20 0.56
FLT3 P36888 1/20 0.56
MKNK2 Q9HBH9 1/20 0.56
MEN1 O00255 2/20 0.54
RECQL P46063 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29397329 1.00 MGAM (1.00) MGAMMAOAFASNMAPTKDM4E
SCHEMBL29405133 1.00 MGAM (1.00) MGAMMAOAFASNMAPTKDM4E
Xanthone SCHEMBL28215604 0.92 MAOA (0.85) MGAMMAOAFASNMAPTKDM4E
SCHEMBL30786757 0.91 MGAM (0.84) MGAMMAOAFASNMAPTKDM4E
SCHEMBL15918267 0.91 MGAM (0.84) MGAMMAOAFASNMAPTKDM4E
SCHEMBL28380092 0.86 MAOA (1.00) MGAMMAOAMAPTKDM4ELMNA
SCHEMBL27857524 0.85 MGAM (0.74) MGAMMAOAFASNMAPTKDM4E
SCHEMBL30015278 0.85 MGAM (0.74) MGAMMAOAFASNMAPTKDM4E
SCHEMBL30346426 0.84 MGAM (0.73) MGAMMAOAFASNMAPTKDM4E
SCHEMBL6907196 0.84 MGAM (0.73) MGAMMAOAFASNMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103350-A1 ANTI-TUMOR AND/OR ANTI-FERROPTOSIS SMALL MOLECULE COMPOSITION AND USE THEREOF 北京慧宝源生物技术股份有限公司 2026-05-21 WO claimed
WO-2026098607-A1 F-18 LABELED AQUEOUS PHARMACEUTICAL COMPOSITION TARGETING LIGAND OF FIBROBLAST ACTIVATION PROTEIN, AND PREPARATION METHOD THEREFOR 天津恒瑞医药有限公司 2026-05-15 WO claimed
US-20250191770-A1 COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE PFIZER INC. (US) 2025-06-12 US claimed
EP-4101437-B1 BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF SHENZHEN EULIKAN BIOTECHNOLOGY CO LTD (CN) 2025-06-11 EP claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-20230329630-A1 COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE PFIZER INC. (US) 2023-10-19 US claimed
CN-116600698-A Computerized decision support tool and medical device for respiratory condition monitoring and care 辉瑞公司 2023-08-15 CN claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
US-20220395481-A1 BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF SHENZHEN EULIKAN BIOTECHNOLOGY CO., LTD (CN) 2022-12-15 US claimed
US-20040152760-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2004-08-05 US claimed
JP-2003532634-A 2003-11-05 JP claimed
EP-1244435-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES Proteotech Inc. (US) 2002-10-02 EP claimed
CN-1345417-A Radiolabelling kit and binding assay IDEC PHARMA CORP (US) 2002-04-17 CN claimed
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2001-11-29 US claimed
WO-2001049281-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES PROTEOTECH, INC. (US) 2001-07-12 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-0496349-B1 Coating solution for preventing adhesion of polymer scale and method for its use SHINETSU CHEMICAL CO (JP) 1996-04-10 EP claimed
US-5314740-A Containing a fluorescent dye in the insulating layer to permit accurate inspection by activation MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1994-05-24 US claimed
EP-0496349-A1 Coating solution for preventing adhesion of polymer scale and method for its use SHIN-ETSU CHEMICAL CO., LTD. (JP) 1992-07-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB MGAM 2363/4885MAOA 3718/4885FASN 1020/4885
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT MGAM 2960/4885MAOA 43/4885FASN 650/4885
US-20040152760-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT MGAM 2960/4885MAOA 43/4885FASN 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.